Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Inclusion Criteria: * Undergone hematopoietic cell transplantation (HCT) ≥21 days or solid organ transplantation (SOT) ≥28 days prior to study treatment administration * Detection of at least 1 target virus of interest (ie, RSV, influenza, hMPV, and/or PIV) * Diagnosis of Upper or mild Lower Respiratory Tract Infection Exclusion Criteria: * Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose \>0.5 mg/kg/day) * Infection by novel coronavirus disease 2019 (COVID-19) * For HCT patients, evidence of Grade \>2 GVHD; and for SOT patients, any history or evidence of GVHD